BMB Reports : eISSN 1976-670X

Cited by CrossRef (35)

  1. Junpeng Zhao, Liming Li, Huiqi Yin, Xiwei Feng, Qianjin Lu. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer. International Immunopharmacology 2023;120:110358
    https://doi.org/10.1016/j.intimp.2023.110358
  2. Yingyan Yu. Multi-target combinatory strategy to overcome tumor immune escape. Front. Med. 2022;16:208
    https://doi.org/10.1007/s11684-022-0922-5
  3. Chang Xu, Hanji Fang, Yun Gu, Kuan Yu, Jieti Wang, Chao Lin, Heng Zhang, He Li, Hongyong He, Hao Liu, Ruochen Li. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer. Cancer Science 2022;113:4070
    https://doi.org/10.1111/cas.15537
  4. Maria V. Deligiorgi, Dimitrios T. Trafalis. The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum. JCM 2022;11:3417
    https://doi.org/10.3390/jcm11123417
  5. Joanne Kite, Monica Hill, Natasha Preston, Anzelika Rubina, Simon Kollnberger, Eddie Chung Yern Wang, Gillian Elliott. Downregulation of endogenous nectin1 in human keratinocytes by herpes simplex virus 1 glycoprotein D excludes superinfection but does not affect NK cell function. 2024;105
    https://doi.org/10.1099/jgv.0.001969
  6. Si‐Jia Zhao, Kahindo P. Muyayalo, Jing Luo, Donghui Huang, Gil Mor, Ai‐Hua Liao. Next generation of immune checkpoint molecules in maternal‐fetal immunity*. Immunological Reviews 2022;308:40
    https://doi.org/10.1111/imr.13073
  7. Ruijia Zhou, Shiyin Chen, Qiwen Wu, Lingyun Liu, Yian Wang, Yongzhen Mo, Zhaoyang Zeng, Xuyu Zu, Wei Xiong, Fuyan Wang. CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Letters 2023;573:216381
    https://doi.org/10.1016/j.canlet.2023.216381
  8. Fengqing Wu, Huan Yang, Xiao Xu, Conglin Ren, Yang Zheng, Helou Zhang, Bingbing Cai, Rui Qiu, Weifan Ren, Renfu Quan, Hannes Stockinger. CD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis. BioMed Research International 2022;2022:1
    https://doi.org/10.1155/2022/3946754
  9. Alice Indini, Daniela Massi, Matteo Pirro, Fausto Roila, Francesco Grossi, Amirhossein Sahebkar, Nicole Glodde, Tobias Bald, Mario Mandalà. Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Seminars in Cancer Biology 2022;86:477
    https://doi.org/10.1016/j.semcancer.2022.06.005
  10. Jakub Klekowski, Dorota Zielińska, Adriana Hofman, Natalia Zajdel, Paweł Gajdzis, Mariusz Chabowski. Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities—A Systematic Review. Cancers 2023;15:3983
    https://doi.org/10.3390/cancers15153983
  11. Peter S. Lee, Bryant Chau, Ishita Barman, Christine Bee, Aarti Jashnani, Jason M. Hogan, Barbara Aguilar, Gavin Dollinger, Arvind Rajpal, Pavel Strop. Antibody blockade of CD96 by distinct molecular mechanisms. mAbs 2021;13
    https://doi.org/10.1080/19420862.2021.1979800
  12. Leah Trumet, Manuel Weber, Alina Hahn, Lina Kunater, Carol Geppert, Jacek Glajzer, Ann-Kristin Struckmeier, Tobias Möst, Rainer Lutz, Marco Kesting, Jutta Ries. The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?. Cancers 2023;15:2126
    https://doi.org/10.3390/cancers15072126
  13. Junpeng Zhao, Liming Li, Xiwei Feng, Xinyu Fan, Huiqi Yin, Qianjin Lu. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE. Lupus 2024;33:209
    https://doi.org/10.1177/09612033241226536
  14. Chelsia Qiuxia Wang, Fong Chan Choy, Arleen Sanny, Takashi Murakami, Andy Hee-Meng Tan, Kong-Peng Lam. An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses. Cells 2023;12:309
    https://doi.org/10.3390/cells12020309
  15. Dana Piovesan, Amber E. de Groot, Soonweng Cho, Amy E. Anderson, Rebecca D. Ray, Amita Patnaik, Paul G. Foster, Casey G. Mitchell, Alejandra Y. Lopez Espinoza, Wandi S. Zhu, Carlo E. Stagnaro, Hema Singh, Xiaoning Zhao, Lisa Seitz, Nigel P. Walker, Matthew J. Walters, Kelsey E. Sivick. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells. 2024;84:1978
    https://doi.org/10.1158/0008-5472.CAN-23-2455
  16. Shenhe Jin, Ye Zhang, Fengping Zhou, Xiaochang Chen, Jianpeng Sheng, Jin Zhang. TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies. Front. Oncol. 2022;12
    https://doi.org/10.3389/fonc.2022.1091782
  17. Jiang-Wan Wu, Ying Liu, Xing-Jie Dai, Hong-Min Liu, Yi-Chao Zheng, Hui-Min Liu. CD155 as an emerging target in tumor immunotherapy. International Immunopharmacology 2024;131:111896
    https://doi.org/10.1016/j.intimp.2024.111896
  18. Neda Haghayegh Jahromi, Anastasia-Olga Gkountidi, Victor Collado-Diaz, Katharina Blatter, Aline Bauer, Lito Zambounis, Jessica Danielly Medina-Sanchez, Erica Russo, Peter Runge, Gaetana Restivo, Epameinondas Gousopoulos, Nicole Lindenblatt, Mitchell P. Levesque, Cornelia Halin. CD112 Supports Lymphatic Migration of Human Dermal Dendritic Cells. Cells 2024;13:424
    https://doi.org/10.3390/cells13050424
  19. Xia Zhou, Sohail Khan, Dabing Huang, Lu Li. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.938470
  20. Katharina Eva Ruppel, Stephan Fricke, Ulrike Köhl, Dominik Schmiedel. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.822298
  21. Dan Qiu, Xiaxin Liu, Wandi Wang, Xuan Jiang, Xiaofang Wu, Jiamian Zheng, Kai Zhou, Xueting Kong, Xiuli Wu, Zhenyi Jin. TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med 2022;23:165
    https://doi.org/10.1007/s10238-022-00817-0
  22. Jingchang Ma, Yitian Liu, Chujun Duan, Shuwen Wu, Yang Xie, Lu Yang, Xuemei Li, Yuling Wang, Yuan Zhang, Ran Zhuang. CD226 knockout reduces the development of CD8+ T by impairing the TCR sensitivity of double‐positive thymocytes. Immunology 2023;169:83
    https://doi.org/10.1111/imm.13612
  23. Long Chen, Fen Huang, Xiaopan Luo, Zan Chen. TREM1 promotes cancer associated malignant phenotype through activated MAPK signaling pathway and predicts poor prognosis in gastric cancer. Heliyon 2024;10:e26852
    https://doi.org/10.1016/j.heliyon.2024.e26852
  24. Xinqiang Li, Shipeng Li, Bin Wu, Qingguo Xu, Dahong Teng, Tongwang Yang, Yandong Sun, Yang Zhao, Tianxiang Li, Dan Liu, Shuang Yang, Weihua Gong, Jinzhen Cai. Landscape of Immune Cells Heterogeneity in Liver Transplantation by Single-Cell RNA Sequencing Analysis. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.890019
  25. Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros. Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. Cancers 2022;14:1710
    https://doi.org/10.3390/cancers14071710
  26. Jakub Kobecki, Paweł Gajdzis, Grzegorz Mazur, Mariusz Chabowski. Nectins and Nectin-like Molecules in Colorectal Cancer: Role in Diagnostics, Prognostic Values, and Emerging Treatment Options: A Literature Review. Diagnostics 2022;12:3076
    https://doi.org/10.3390/diagnostics12123076
  27. Fenling Zhou, Lu Chen, Peng Lu, Yuli Cao, Cuilan Deng, Gexiu Liu. An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma. BMC Cancer 2023;23
    https://doi.org/10.1186/s12885-023-11108-6
  28. Katharina Seel, Ronja Larissa Schirrmann, Daniel Stowitschek, Tamar Ioseliani, Lea Roiter, Alina Knierim, Maya C. André. Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia. Cancer Immunol Immunother 2024;73
    https://doi.org/10.1007/s00262-024-03766-7
  29. Manuel Weber, Rainer Lutz, Manuel Olmos, Jacek Glajzer, Christoph Baran, Christopher-Philipp Nobis, Tobias Möst, Markus Eckstein, Marco Kesting, Jutta Ries. Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer. Cancers 2022;14:1812
    https://doi.org/10.3390/cancers14071812
  30. Ahmed Rishiq, Reem Bsoul, Ophir Pick, Ofer Mandelboim. Studying TIGIT activity against tumors through the generation of knockout mice. OncoImmunology 2023;12
    https://doi.org/10.1080/2162402X.2023.2217735
  31. Sara Sadat Aghamiri, Bhanwar Lal Puniya, Rada Amin, Tomáš Helikar. A multiscale mechanistic model of human dendritic cells for in-silico investigation of immune responses and novel therapeutics discovery. Front. Immunol. 2023;14
    https://doi.org/10.3389/fimmu.2023.1112985
  32. SJ J. Diong, Aarti Jashnani, Andrew W. Drake, Christine Bee, Felix Findeisen, Gavin Dollinger, Feng Wang, Arvind Rajpal, Pavel Strop, Peter S. Lee. Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT. mAbs 2023;15
    https://doi.org/10.1080/19420862.2023.2253788
  33. David Jeremie Birnbaum, Maelle Picard, Quentin Da Costa, Thomas Delayre, Pascal Finetti, Olivier Cabaud, Emilie Agavnian, Bernadette De Rauglaudre, Emilie Denicolaï, François Bertucci, Emilie Mamessier. PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma. Cancers 2023;15:447
    https://doi.org/10.3390/cancers15020447
  34. Qiaxuan Li, Daipeng Xie, Lintong Yao, Hongrui Qiu, Peimeng You, Jialong Deng, Congsen Li, Weijie Zhan, Maotao Weng, Shaowei Wu, Fasheng Li, Yubo Zhou, Fanjun Zeng, Yong Zheng, Haiyu Zhou. Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma. Front. Immunol. 2022;13
    https://doi.org/10.3389/fimmu.2022.944378
  35. Cristina Capuano, Chiara Pighi, Simone Battella, Davide De Federicis, Ricciarda Galandrini, Gabriella Palmieri. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers 2021;13:2500
    https://doi.org/10.3390/cancers13102500